Rocket Pharmaceuticals Inc (RCKT)
13.98
-0.84
(-5.67%)
USD |
NASDAQ |
Nov 15, 16:00
14.06
+0.08
(+0.57%)
After-Hours: 20:00
Rocket Pharmaceuticals Enterprise Value: 1.039B for Nov. 15, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 15, 2024 | 1.039B |
| November 14, 2024 | 1.115B |
| November 13, 2024 | 1.193B |
| November 12, 2024 | 1.226B |
| November 11, 2024 | 1.301B |
| November 08, 2024 | 1.355B |
| November 07, 2024 | 1.337B |
| November 06, 2024 | 1.367B |
| November 05, 2024 | 1.331B |
| November 04, 2024 | 1.297B |
| November 01, 2024 | 1.311B |
| October 31, 2024 | 1.281B |
| October 30, 2024 | 1.311B |
| October 29, 2024 | 1.345B |
| October 28, 2024 | 1.358B |
| October 25, 2024 | 1.317B |
| October 24, 2024 | 1.333B |
| October 23, 2024 | 1.367B |
| October 22, 2024 | 1.377B |
| October 21, 2024 | 1.370B |
| October 18, 2024 | 1.479B |
| October 17, 2024 | 1.444B |
| October 16, 2024 | 1.410B |
| October 15, 2024 | 1.284B |
| October 14, 2024 | 1.304B |
| Date | Value |
|---|---|
| October 11, 2024 | 1.323B |
| October 10, 2024 | 1.272B |
| October 09, 2024 | 1.280B |
| October 08, 2024 | 1.336B |
| October 07, 2024 | 1.292B |
| October 04, 2024 | 1.260B |
| October 03, 2024 | 1.228B |
| October 02, 2024 | 1.310B |
| October 01, 2024 | 1.324B |
| September 30, 2024 | 1.447B |
| September 27, 2024 | 1.401B |
| September 26, 2024 | 1.322B |
| September 25, 2024 | 1.401B |
| September 24, 2024 | 1.385B |
| September 23, 2024 | 1.521B |
| September 20, 2024 | 1.556B |
| September 19, 2024 | 1.664B |
| September 18, 2024 | 1.617B |
| September 17, 2024 | 1.704B |
| September 16, 2024 | 1.468B |
| September 13, 2024 | 1.509B |
| September 12, 2024 | 1.444B |
| September 11, 2024 | 1.452B |
| September 10, 2024 | 1.503B |
| September 09, 2024 | 1.516B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
177.48M
Minimum
May 11 2022
3.577B
Maximum
Feb 08 2021
1.395B
Average
1.274B
Median
Enterprise Value Benchmarks
| Apellis Pharmaceuticals Inc | 3.323B |
| NovaBay Pharmaceuticals Inc | 2.764M |
| Palatin Technologies Inc | 8.735M |
| iBio Inc | 6.468M |
| Theriva Biologics Inc | -13.32M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -66.72M |
| Total Expenses (Quarterly) | 69.42M |
| EPS Diluted (Quarterly) | -0.71 |
| Earnings Yield | -19.67% |